What you can and cannot say about a research peptide

Two agencies are reading your marketing, and they divide the work. FDA has primary jurisdiction over labeling. FTC has primary jurisdiction over advertising. On peptides they coordinate, so it is not useful to think of them as separate audiences.

What matters for a seller is that there is a line, it is reasonably well defined, and most operators cross it without realising there was a line to cross.

The line: structure/function versus disease

The distinction that governs almost everything:

• A structure/function claim describes an effect on the normal structure or function of the body. These are permissible with adequate substantiation.
• A disease claim implies diagnosis, cure, mitigation, treatment, or prevention of a disease. These require FDA drug approval, full stop. There is no substantiation package that makes a disease claim acceptable for an unapproved product.

The second category is the bright line. If your copy implies your product treats, prevents, or mitigates a condition, no disclaimer rescues it and no study you cite makes it permissible.

The substantiation bar on everything else

Even permissible claims are not free. FTC's Health Products Compliance Guidance requires health benefit claims to be supported by “competent and reliable scientific evidence,” and its stated expectation leans toward randomised controlled human clinical trials.

What does not clear that bar on its own:

• Animal studies
• In vitro studies
• Anecdotes and customer reports
• Observational studies, except where experts in the field consider them an adequate substitute and clinical trials are not feasible

Worth being precise here, because this gets overstated in both directions. This is FTC guidance, not binding statute, and some practitioners note that FTC Act case law does not strictly require randomised trials in every circumstance. The honest position is that the guidance sets a high expectation, the case law is somewhat more flexible, and unless qualified counsel has told you specifically where you sit, the safe operating assumption is the high bar.

For most research-peptide sellers the practical consequence is simple: the human clinical evidence that would substantiate a benefit claim does not exist for these compounds. That is precisely why they are sold for research rather than for use. If you had the evidence to make the claim, you would not need the research-use framing.

The phrases that have drawn attention

Gray-zone language that FDA and FTC have targeted in this category:

• “promotes recovery”
• “GH boost”
• “anti-aging”
• “neuroprotective”
• “promotes tendon healing”

Notice that none of these name a disease. That is the point. They imply a benefit in a person, which is enough to put a product outside research framing, and hedged verbs like “promotes” and “supports” do not soften them meaningfully.

Totality of marketing

The single most useful concept to internalise: your compliance posture is judged across everything you publish, not page by page.

That includes:

• Product pages and product titles
• Blog posts and guides
• Email and SMS
• Social posts, including replies
• Affiliate and influencer content published on your behalf
• Customer reviews you display, and how you moderate them
• Bundle and collection names
• Anything a person could reasonably reach from your storefront

A compliant product page underneath a blog post making benefit claims is not a compliant site. This is also why the cleanup cannot be a one-time project: the site drifts as soon as someone writes a subject line under pressure to hit a number.

What you can say, which is more than people think

Operators hear all of this and conclude they have nothing left to write. That is not right, and the brands doing well in this category prove it. You can talk about:

• Purity and testing. Third-party results, the assay used, the lab that ran it.
• Lot traceability. A certificate of analysis for the specific lot in the box.
• Handling and storage. Cold chain, lyophilisation, storage conditions, shipping method.
• The compound itself. What it is, its molecular weight, its CAS number, what it is studied for in the literature, described as research rather than as a benefit to the reader.
• Your operation. Sourcing standards, quality process, how you handle a bad lot, how fast you ship, how you answer support.
• Documentation. What arrives with the order and what is verifiable.

That is a real differentiation story, and it is the one a serious buyer is actually evaluating. Most sites in this category are interchangeable precisely because they compete on implied benefit rather than on any of the above.

A test that works

Before publishing anything, two questions:

1. Delete every disclaimer. What would a reasonable person conclude the product is for? If the answer involves their own body, rewrite.
2. Could I substantiate this with human clinical evidence if asked tomorrow? If not, it is not a claim you can make, regardless of how it is hedged.

Both questions are answerable by whoever is writing the copy, which is the useful part. This does not require counsel on every sentence. It requires one rule applied consistently, and counsel for the genuinely uncertain cases.

This guide is general information, not legal advice. It summarises publicly available FDA and FTC guidance and enforcement patterns as of writing; guidance is not binding statute, agency positions and case law evolve, and application depends on your specific products and copy. Consult qualified regulatory counsel before relying on any of it.